These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19236266)

  • 1. Apricitabine--a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs.
    Cox S; Southby J
    Expert Opin Investig Drugs; 2009 Feb; 18(2):199-209. PubMed ID: 19236266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
    Cahn P; Wainberg MA
    J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.
    Wainberg MA; Cahn P; Bethell RC; Sawyer J; Cox S
    Antivir Chem Chemother; 2007; 18(2):61-70. PubMed ID: 17542150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.
    Cahn P; Altclas J; Martins M; Losso M; Cassetti I; Cooper DA; Cox S
    HIV Med; 2011 Jul; 12(6):334-42. PubMed ID: 21054750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improved long-term success. New nucleoside for once daily combinations].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043
    [No Abstract]   [Full Text] [Related]  

  • 6. Apricitabine: a nucleoside reverse transcriptase inhibitor for HIV infection.
    Gaffney MM; Belliveau PP; Spooner LM
    Ann Pharmacother; 2009 Oct; 43(10):1676-83. PubMed ID: 19737995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection.
    Cahn P; Rolon M; Cassetti I; Shiveley L; Holdich T; Sawyer J
    Clin Drug Investig; 2008; 28(2):129-38. PubMed ID: 18211121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
    Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
    J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.
    Molina JM; Cox SL
    Drugs Today (Barc); 2005 Apr; 41(4):241-52. PubMed ID: 16034488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor.
    Richman DD
    Antivir Ther; 2001 Jun; 6(2):83-8. PubMed ID: 11491420
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.
    Cahn P; Cassetti I; Wood R; Phanuphak P; Shiveley L; Bethell RC; Sawyer J
    AIDS; 2006 Jun; 20(9):1261-8. PubMed ID: 16816554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Approval of a new nucleoside. Component of complete once daily regimen].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
    [No Abstract]   [Full Text] [Related]  

  • 19. New nucleoside/nucleotide backbone options: a review of recent studies.
    Ruane PJ; DeJesus E
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S21-9. PubMed ID: 15319666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.